Mubadala announces reinvestment in PCI Pharma Services

Image: Getty Images

Mubadala Investment Company, the Abu Dhabi-based sovereign investor, said on Monday it has entered into an agreement to make a significant reinvestment in PCI Pharma Services, a global contract development and manufacturing organisation (CDMO) focused on biotherapies.

The deal is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg. Partners Group will also remain involved with a minority investment, Mubadala said in a statement.

Mubadala first invested in PCI alongside Kohlberg in 2020.

PCI has been expanding its presence in pharma

Over the past five years, PCI has delivered more than 450 product launches and continues to build on its 50-year history in pharmaceutical services.

“PCI Pharma Services has been one of our top-performing healthcare investments and is a testament to what can be achieved when long-term active investors partner with strong management teams,” said Camilla Languille, co-CEO of Private Equity at Mubadala.

“Our team will continue to focus on similar opportunities in the healthcare space as the sustained outsourcing of mission-critical but non-core activities by pharma companies aligns with our commitment to address global unmet clinical needs, reduce the cost of care to the system, and enable greater access,” she added.

Mubadala investment reflects PCI’s potential

Mina Hamoodi, head of Healthcare at Mubadala, said: “Our reinvestment in PCI reflects our deep conviction in the company’s mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner.”

She added that Mubadala looks forward to partnering with Bain and Kohlberg and working closely with PCI’s management as the company enters its “next chapter of accelerated growth”.

The new investment will support both organic and inorganic expansion, including growth in sterile fill-finish injectables, high-potency drug manufacturing, and specialised therapies.

The company also plans continued investment in the United States to strengthen domestic pharmaceutical manufacturing and supply chain resilience.